Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine

Michael D. Wiese, Vijay Suppiah, Catherine King

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: A number of disease-modifying therapies have become available to treat multiple sclerosis (MS) in recent years. As the effects of these medications are unpredictable and they are generally used for a number of years, the selection of the most appropriate disease-modifying agent must be based on the long-term efficacy and toxicity profile, thus strategies to personalise treatment to optimise responses may be potentially very useful.Areas covered: This review provides an overview of the efficacy and toxicity of disease-modifying agents used in MS and specifically discusses any metabolic side effects and advances in personalising the use of each of these agents. Medline and EMBASE were searched for any articles regarding the efficacy, toxicity and personalised use of the medicines discussed in this review.Expert opinion: Disease-modifying agents used to treat MS differ substantially in their efficacy and toxicity profile, but metabolic side effects appear to be limited to alemtuzumab, teriflunomide and IFN-β. Although personalised treatment strategies to assist in selection of the most appropriate disease-modifying agent for MS are limited, there is substantial potential to use genetic sub-studies of the many recent trials investigating disease-modifying agents to develop personalised treatment strategies.

LanguageEnglish
Pages1145-1159
Number of pages15
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number8
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Keywords

  • Adverse drug reaction
  • Metabolic effects
  • Multiple sclerosis
  • Personalised medicine
  • Pharmacotherapy

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{556c56428dd3408cab541557368703ba,
title = "Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine",
abstract = "Introduction: A number of disease-modifying therapies have become available to treat multiple sclerosis (MS) in recent years. As the effects of these medications are unpredictable and they are generally used for a number of years, the selection of the most appropriate disease-modifying agent must be based on the long-term efficacy and toxicity profile, thus strategies to personalise treatment to optimise responses may be potentially very useful.Areas covered: This review provides an overview of the efficacy and toxicity of disease-modifying agents used in MS and specifically discusses any metabolic side effects and advances in personalising the use of each of these agents. Medline and EMBASE were searched for any articles regarding the efficacy, toxicity and personalised use of the medicines discussed in this review.Expert opinion: Disease-modifying agents used to treat MS differ substantially in their efficacy and toxicity profile, but metabolic side effects appear to be limited to alemtuzumab, teriflunomide and IFN-β. Although personalised treatment strategies to assist in selection of the most appropriate disease-modifying agent for MS are limited, there is substantial potential to use genetic sub-studies of the many recent trials investigating disease-modifying agents to develop personalised treatment strategies.",
keywords = "Adverse drug reaction, Metabolic effects, Multiple sclerosis, Personalised medicine, Pharmacotherapy",
author = "Wiese, {Michael D.} and Vijay Suppiah and Catherine King",
year = "2014",
month = "1",
day = "1",
doi = "10.1517/17425255.2014.925880",
language = "English",
volume = "10",
pages = "1145--1159",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
number = "8",

}

Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine. / Wiese, Michael D.; Suppiah, Vijay; King, Catherine.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 8, 01.01.2014, p. 1145-1159.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Metabolic and safety issues for multiple sclerosis pharmacotherapy- opportunities for personalised medicine

AU - Wiese, Michael D.

AU - Suppiah, Vijay

AU - King, Catherine

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: A number of disease-modifying therapies have become available to treat multiple sclerosis (MS) in recent years. As the effects of these medications are unpredictable and they are generally used for a number of years, the selection of the most appropriate disease-modifying agent must be based on the long-term efficacy and toxicity profile, thus strategies to personalise treatment to optimise responses may be potentially very useful.Areas covered: This review provides an overview of the efficacy and toxicity of disease-modifying agents used in MS and specifically discusses any metabolic side effects and advances in personalising the use of each of these agents. Medline and EMBASE were searched for any articles regarding the efficacy, toxicity and personalised use of the medicines discussed in this review.Expert opinion: Disease-modifying agents used to treat MS differ substantially in their efficacy and toxicity profile, but metabolic side effects appear to be limited to alemtuzumab, teriflunomide and IFN-β. Although personalised treatment strategies to assist in selection of the most appropriate disease-modifying agent for MS are limited, there is substantial potential to use genetic sub-studies of the many recent trials investigating disease-modifying agents to develop personalised treatment strategies.

AB - Introduction: A number of disease-modifying therapies have become available to treat multiple sclerosis (MS) in recent years. As the effects of these medications are unpredictable and they are generally used for a number of years, the selection of the most appropriate disease-modifying agent must be based on the long-term efficacy and toxicity profile, thus strategies to personalise treatment to optimise responses may be potentially very useful.Areas covered: This review provides an overview of the efficacy and toxicity of disease-modifying agents used in MS and specifically discusses any metabolic side effects and advances in personalising the use of each of these agents. Medline and EMBASE were searched for any articles regarding the efficacy, toxicity and personalised use of the medicines discussed in this review.Expert opinion: Disease-modifying agents used to treat MS differ substantially in their efficacy and toxicity profile, but metabolic side effects appear to be limited to alemtuzumab, teriflunomide and IFN-β. Although personalised treatment strategies to assist in selection of the most appropriate disease-modifying agent for MS are limited, there is substantial potential to use genetic sub-studies of the many recent trials investigating disease-modifying agents to develop personalised treatment strategies.

KW - Adverse drug reaction

KW - Metabolic effects

KW - Multiple sclerosis

KW - Personalised medicine

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84904322465&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.925880

DO - 10.1517/17425255.2014.925880

M3 - Review article

VL - 10

SP - 1145

EP - 1159

JO - Expert Opinion on Drug Metabolism and Toxicology

T2 - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 8

ER -